Results 11 to 20 of about 1,056 (174)

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis [PDF]

New England Journal of Medicine, 2023
Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis.In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to ...
Kwatra, Shawn G, Yosipovitch, Gil, Legat, Franz J, Reich, Adam, Paul, Carle, Simon, Dagmar, Naldi, Luigi, Lynde, Charles, De Bruin-Weller, Marjolein S, Nahm, Walter K, Sauder, Maxwell, Gharib, Rola, Barbarot, Sebastien, Szepietowski, Jacek C, Conrad, Curdin, Fleischer, Alan, Laquer, Vivian T, Misery, Laurent, Serra-Baldrich, Esther, Lapeere, Hilde, Ahmad, Faiz, Jabbar Lopez, Zarif K, Piketty, Christophe, Ständer, Sonja, Schuttelaar, Marielouise   +24 more
core   +8 more sources

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

New England Journal of Medicine, 2020
Prurigo nodularis is a chronic pruritic skin disease with multiple nodular skin lesions. Nemolizumab is a monoclonal antibody targeting the interleukin-31 receptor, which is involved in the pathogenesis of prurigo nodularis.We conducted a 12-week, randomized, double-blind, phase 2 trial of nemolizumab (at a dose of 0.5 mg per kilogram of body weight ...
Sonja, Ständer, Gil, Yosipovitch, Franz J, Legat, Jean-Philippe, Lacour, Carle, Paul, Joanna, Narbutt, Thomas, Bieber, Laurent, Misery, Andreas, Wollenberg, Adam, Reich, Faiz, Ahmad, Christophe, Piketty   +11 more
openaire   +3 more sources

Novel therapeutic use of nemolizumab for refractory chronic scalp dysesthesia [PDF]

JAAD Case Reports
Lauren Kuan, BA, Theodore Mah, Peter B. Chansky, MD   +2 more
doaj   +4 more sources

24-week real world outcomes of nemolizumab in patients with prurigo nodularis

Journal of Dermatological Treatment
Backgrounds Prurigo nodularis (PN) is a chronic pruritic inflammatory disease associated with immune and neural dysregulation. Although nemolizumab has demonstrated efficacy in clinical trials, real-world post-marketing data remain limited.Objective To ...
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +2 more sources

Efficacy and safety of nemolizumab in prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials [PDF]

Anais Brasileiros de Dermatologia
Background Prurigo nodularis (PN) is a chronic, debilitating inflammatory skin disorder characterized by persistent itching, firm pruritic nodular lesions, and evidence of frequent scratching, like excoriation, and lichenification.
Ana Carolina Putini Vieira, Maria Antônia Costa Cruz Akabane, Gianna Carolinne Graff Caletti, Kélen Klein Heffel, Amanda Tauana Oliveira e Silva   +4 more
doaj   +2 more sources

Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis. [PDF]

Br J Clin Pharmacol
Abstract Aims Population pharmacokinetic (popPK) and pharmacokinetic‐pharmacodynamic (PK/PD) models were developed to support clinical development of nemolizumab, a humanized monoclonal antibody targeting the IL‐31 receptor α, in adolescents and adults with moderate‐to‐severe atopic dermatitis (AD).
Fauchet F, Largajolli A, Jauslin PM, Schindler E, Hamimed M, Kantasiripitak W, Gonçalves A, Van Maanen E, Benkali K, Saito T, Silverberg JI, Wollenberg A, Graeber M, Ulianov L, Piketty C, Loprete L, Duval V, Wagner N.   +17 more
europepmc   +2 more sources

Comparative safety profiles of dupilumab and nemolizumab in prurigo nodularis: an indirect META-analysis to inform clinical decision-making [PDF]

Frontiers in Medicine
BackgroundPrurigo nodularis (PN), a chronic inflammatory skin disease with significant disease burden, lacks effective therapies. Dupilumab (IL-4Rα inhibitor) and nemolizumab (IL-31 receptor antagonist) show efficacy in trials but have heterogeneous ...
Wenzhe Feng, Dongyang Wang, Kaiyue Tan, Xiaojie Zhang   +3 more
doaj   +2 more sources

Cutaneous Adverse Events Following Nemolizumab Administration: A Review

Journal of Clinical Medicine
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by epidermal barrier dysfunction and immune dysregulation, with interleukin (IL)-4, IL-13, and IL-31 recognized as key mediators. Prurigo nodularis (PN) is another chronic inflammatory disorder driven by T helper type 2-mediated inflammation and neural dysregulation, leading to
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
openaire   +3 more sources

Nemolizumab as an Alternative Therapeutic Option for Indolent Systemic Mastocytosis. [PDF]

Cureus
Indolent systemic mastocytosis (ISM) is a clonal mast cell disorder characterized by recurrent symptoms that can persist despite treatment with antihistamines, leukotriene antagonists, and mast cell stabilizers. Treatment options are limited when symptoms remain refractory, and avapritinib is contraindicated or declined.
Minbaeva S, Tyring SK.
europepmc   +3 more sources

Real-World, Single-Center Analysis of Cutaneous Adverse Events with Nemolizumab: Toward Safer and More Effective Use [PDF]

Journal of Clinical Medicine
Background/Objectives: Nemolizumab provides rapid and effective relief from pruritus in patients with atopic dermatitis. However, it is frequently associated with cutaneous adverse events, and reliable predictors of their severity have not yet been ...
Akiko Sugiyama, Takeshi Nakahara
exaly   +3 more sources